Latest Hotspot

Corteria Pharmaceuticals Initiates Phase 1 Trial for Heart Failure Drug COR-1167

29 March 2024
3 min read

Corteria Pharmaceuticals, which is actively engaged in the advancement of innovative treatments for cardiovascular malfunctions and weight management issues, publicly declared the commencement of their Phase 1 clinical trial. This examination is designed to assess their pioneering compound, COR-1167, an activator of the corticotropin-releasing hormone receptor 2 (CRF2). The investigational drug is aimed at addressing patients with progressive deterioration in heart function.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

COR-1167 is administered once daily via a subcutaneous injection and functions as an activator of the CRF2 receptor. It has shown notable benefits, improving cardiac, vascular, and renal functions in a variety of heart failure animal studies. The distinctive way in which COR-1167 works presents a new therapeutic angle to address WHF; its primary therapeutic aim is to relieve heart stress by preserving and enhancing circulatory and kidney stability.

The initial phase of the clinical trials involves a study where the participants are randomly assigned to either receive COR-1167 or a placebo, with the key goal being to evaluate the compound’s safety and the body's ability to tolerate it in both individuals who are healthy and those living with chronic heart failure.

The progression of our preliminary CRF2 receptor activator to the clinical trial phase marks a pivotal development in our pursuit of alternative treatments for patients suffering from WHF,” Philip Janiak, the creator and chief executive of Corteria Pharmaceuticals, articulated. “The data obtained from preclinical research on COR-1167 looks highly encouraging, and we're eager to assess its potential to treat patients.”

Prof. Adriaan Voors, a cardiology expert at the University Medical Centre Groningen and the chief researcher for this trial, highlighted the significance of this Phase 1 trial which focuses on COR-1167: “Implementing this clinical trial for a CRF2 receptor activator in both healthy individuals and those suffering from heart failure marks a crucial development towards lessening the impact of heart failure. This is especially vital for patients who still struggle with deteriorating conditions even after following existing recommended treatment protocols.”

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of March 27, 2024, there are 8 investigational drugs for the CRHR2 target, including 13 indications, 13 R&D institutions involved, with related clinical trials reaching 8, and as many as 1142 patents.

COR-1167 targets CRHR2, a receptor involved in cardiovascular diseases. While still in the preclinical phase, the drug shows promise in potentially improving cardiac function and addressing the unmet medical need in heart failure. Further research and development will be necessary to determine its safety and efficacy in human clinical trials.

图形用户界面, 文本, 应用程序

描述已自动生成

Explore Levocetirizine on Synapse: Tips and Tricks for Better Search Results
Drug Insights
2 min read
Explore Levocetirizine on Synapse: Tips and Tricks for Better Search Results
29 March 2024
Levocetirizine is a small, powerful drug that works as an H1 receptor antagonist to treat various allergies, including respiratory issues, dermatitis, and eczema.
Read →
Intravacc reveals encouraging initial human trial results for its novel OMV nasal spray vaccine against COVID-19
Latest Hotspot
3 min read
Intravacc reveals encouraging initial human trial results for its novel OMV nasal spray vaccine against COVID-19
29 March 2024
Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.
Read →
What is Bioequivalence?
"What" Series
2 min read
What is Bioequivalence?
29 March 2024
Bioequivalence is a pharmacological term used to describe the similarity in the pharmacokinetic profiles of two drug products, usually a brand-name drug and a generic drug.
Read →
AST-201: Aptamer Sciences' Novel Therapy for Liver Cancer in NDA Submission
Latest Hotspot
4 min read
AST-201: Aptamer Sciences' Novel Therapy for Liver Cancer in NDA Submission
29 March 2024
Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.